Founded in 2018, Giam Pharma was established to develop intelligent oncology therapies.

Fraisinib: Innovation Against Tumors Resistant to Conventional Therapies

The first molecule to inhibit GARS1 for targeted and tolerable treatments.

Learn More
Key Highlights

Core Strengths

Preclinical Trials
International Patent Protection
Very Low Systemic Toxicity
Publications
  • Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology - Frontiers in Pharmacology (2024)
  • Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer - Investigational New Drugs (2022)
  • A novel calix[4]pyrrole derivative as a potential anticancer agent that forms genotoxic adducts with DNA – Scientific Reports (2018)

Are you an investor? Discover why Fraisinib can make a difference.

● Updates